Cytotheryx is a preclinical cell therapy company focused on the development of a consistent, high-quality source of human hepatocytes.
Cytotheryx has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
Cytotheryx's investors include Ouroboros Family Founders Fund I, QRS Investments.
Cytotheryx is headquartered in Rochester, United States.
Cytotheryx is a preclinical cell therapy company focused on the development of a consistent, high-quality source of human hepatocytes.
Cytotheryx is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cytotheryx — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/cytotheryx. Accessed September 30, 2026.
VCBacked. (2026). Cytotheryx — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cytotheryx
{{cite web |title=Cytotheryx — Funding & Investors |url=https://www.vcbacked.co/company/cytotheryx |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated